This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $38.22, moving -0.68% from the previous trading session.
Amgen Gets FDA Approval for J&J/Merck's Remicade Biosimilar
by Zacks Equity Research
FDA gives nod to Amgen's (AMGN) Avsola (ABP 710), a biosimilar of J&J's blockbuster rheumatoid arthritis drug, Remicade.
Pharma Stock Roundup: FDA Updates for RHHBY, AZN, MRK, No Asbestos in Talc Says JNJ
by Kinjel Shah
The FDA approves Roche's (RHHBY) Tecentriq for expanded use. It grants priority review status to AstraZeneca (AZN) & Merck's (MRK) supplemental applications.
Glaxo Files NDA for Fostemsavir for Heavily Pre-Treated HIV
by Zacks Equity Research
Glaxo (GSK) submits a new drug application to the FDA for its first-in-class attachment inhibitor fostemsavir, which is being evaluated for the treatment of HIV-1 infection.
Bristol-Myers' Orencia Gets Breakthrough Therapy Tag for GvHD
by Zacks Equity Research
The FDA grants Breakthrough Therapy designation to Bristol-Myers Squibb's (BMY) Orencia for the prevention of moderate-to-severe acute GvHD in hematopoietic SCT from unrelated donors.
Pfizer/Astellas Xtandi Gets Nod in China for Prostate Cancer (Revised)
by Zacks Equity Research
Pfizer (PFE)/Astellas' Xtandi gets approval in China to treat metastatic castration-resistant prostate cancer (CRPC).
Mylan (MYL) Launches Herceptin Biosimilar Ogivri in the US
by Zacks Equity Research
Mylan (MYL) launches Ogivri, a biosimilar of Roche's blockbuster breast cancer drug, Herceptin (trastuzumab), in the United States.
Merck's Keytruda Gets FDA's Priority Tag in Bladder Cancer
by Zacks Equity Research
Merck's (MRK) sBLA for Keytruda gets FDA's priority review status to treat certain patients with high-risk, non-muscle invasive bladder cancer.
Large-Cap Pharmaceuticals Industry Prospects Bright for 2020
by Kinjel Shah
The Zacks Large Cap Pharmaceuticals industry ranks in the top 13% of more than 250 Zacks industries.
AstraZeneca's (AZN) Imfinzi Gets FDA Priority Tag for SCLC
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi, if approved for extensive-stage small cell lung cancer, can cater to a broader lung cancer patient population, which can bring in additional sales.
Why Is Pfizer (PFE) Up 0.4% Since Last Earnings Report?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Merck's (MRK) Shares Are Up This Year
by Zacks Equity Research
Merck's (MRK) shares are up 11.7% this year so far on strong performance and positive regulatory updates on its PD-1 inhibitor Keytruda.
Merck's Keytruda Gets Nod in China for Difficult Lung Cancer
by Zacks Equity Research
Merck (MRK) receives the third approval of Keytruda for first-line non-small cell lung cancer patient population in China.
Pfizer/Astellas Xtandi Gets Nod in China for Prostate Cancer
by Zacks Equity Research
Pfizer (PFE)/Astellas' Xtandi gets approval in China to treat metastatic castration-resistant prostate cancer (CRPC).
The Zacks Analyst Blog Highlights: Pfizer, Netflix, Dominion, Costco and Charles Schwab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Netflix, Dominion, Costco and Charles Schwab
Pharma Stock Roundup: FDA Nod to NVS' & AZN's Drugs, BMY-CELG Merger Closes
by Kinjel Shah
The FDA approves Novartis' (NVS) sickle cell disease candidate Adakveo and AstraZeneca's (AZN) Calquence for chronic lymphocytic leukemia. Bristol-Myers (BMY) completes $74 billion-buyout of Celgene.
BioMarin Files MAA to EMA for Gene Therapy of Hemophilia A
by Zacks Equity Research
BioMarin (BMRN) submits an MAA in Europe for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
Amgen (AMGN) Completes Otezla Buyout, Raises 2019 Guidance
by Zacks Equity Research
Amgen (AMGN) concludes the pending buyout of Celgene's psoriasis drug Otezla to acquire its worldwide rights. The company also hikes its overall 2019 view. Stock gains.
Top Research Reports for Pfizer, Netflix & Dominion Energy
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Netflix (NFLX) and Dominion Energy (D).
Merck's Keytruda Wins EU Nod for First-Line Head/Neck Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda gets approval in Europe to treat first-line head/neck cancer based on data from the phase III KEYNOTE-048 study.
Pfizer Gets FDA Approval for Biosimilar of AbbVie's Humira
by Zacks Equity Research
The approval of Humira biosimilar is the fourth U.S. approval of a biosimilar product for Pfizer (PFE) in 2019.
Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex
by Zacks Equity Research
Aerie (AERI) will acquire Spanish ophthalmic pharmaceutical company, Avizorex Pharma, to add a mid-stage dry eye disease candidate to its pipeline.
How Pfizer (PFE) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Pfizer (PFE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Stock Market News for Nov 18, 2019
by Zacks Equity Research
Benchmarks closed at record highs on Friday on U.S.-China trade deal hopes in spite of mixed economic data.
Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates
by Kinjel Shah
Merck (MRK) gets approval in Europe for Ebola vaccine. Roche, Glaxo (GSK) & Pfizer (PFE) provide pipeline updates.